Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) EVP Myriam Curet sold 8,819 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $300.00, for a total value of $2,645,700.00. Following the transaction, the executive vice president now directly owns 189 shares in the company, valued at $56,700. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Intuitive Surgical Stock Performance
NASDAQ ISRG traded up $2.47 on Friday, hitting $306.42. 2,216,025 shares of the stock traded hands, compared to its average volume of 1,768,631. The business’s fifty day moving average is $284.12 and its two-hundred day moving average is $305.07. Intuitive Surgical, Inc. has a 12 month low of $222.65 and a 12 month high of $358.07. The firm has a market capitalization of $107.88 billion, a price-to-earnings ratio of 72.29, a PEG ratio of 4.85 and a beta of 1.31.
Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last announced its quarterly earnings data on Thursday, October 19th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.06. Intuitive Surgical had a return on equity of 12.91% and a net margin of 22.14%. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.77 billion. During the same period in the prior year, the company earned $0.90 earnings per share. Intuitive Surgical’s revenue was up 12.0% compared to the same quarter last year. Analysts expect that Intuitive Surgical, Inc. will post 4.54 EPS for the current fiscal year.
Hedge Funds Weigh In On Intuitive Surgical
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on ISRG shares. JPMorgan Chase & Co. upped their price target on Intuitive Surgical from $335.00 to $365.00 and gave the stock an “overweight” rating in a research note on Friday, July 21st. StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. TheStreet raised Intuitive Surgical from a “c+” rating to a “b” rating in a research note on Monday, July 24th. Citigroup lowered their price objective on Intuitive Surgical from $400.00 to $390.00 and set a “buy” rating for the company in a research note on Friday, October 20th. Finally, Morgan Stanley lowered their price objective on Intuitive Surgical from $330.00 to $300.00 and set an “equal weight” rating for the company in a research note on Monday, October 23rd. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $341.05.
Intuitive Surgical Company Profile
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
- Five stocks we like better than Intuitive Surgical
- How to Invest in Fertilizer
- 3 large caps with red hot RSIs with upside
- Stock Market Upgrades: What Are They?
- Johnson Controls International: Nothing but upside for investors
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.